DEF: Sanara MedTech 2026 Annual Meeting Proxy Statement

Sanara MedTech Inc. has issued its 2026 Proxy Statement detailing the upcoming virtual Annual Meeting of Shareholders scheduled for June 4, 2026.

Summary

• The 2026 Annual Meeting of Shareholders will be held virtually on June 4, 2026, at 10:00 a.m. Central Time.
• Shareholders will vote on the election of nine directors, ratification of Weaver and Tidwell, L.L.P. as the independent auditor, advisory approval of executive compensation, and the frequency of future advisory votes on executive compensation.
• The Board recommends voting FOR all director nominees, FOR the auditor ratification, FOR the executive compensation, and for a 3-YEAR frequency for future advisory votes.
• The record date for voting is April 8, 2026, with 9,164,757 shares of common stock issued and outstanding.
• The company has undergone leadership changes, including the appointment of Seth D. Yon as President and CEO effective September 15, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook due to the substantial increase in net losses and the ongoing strategic pivot, despite the stability provided by the new leadership team.

Positives

• The company has successfully transitioned to a new leadership team, with Seth D. Yon appointed as President and CEO.
• The company maintains a robust corporate governance structure with independent committees for audit, compensation, and corporate development.
• The company has established clear long-term incentive plans (2024 Plan) to align executive interests with shareholder value.

Negatives

• The company reported a significant net loss of $37,562,606 for the 2025 fiscal year.
• The company is in the process of terminating the Debrider License Agreement with Rochal Industries, LLC.
• The company discontinued operations of Tissue Health Plus, LLC in September 2025.

Risks

• The company faces risks associated with its strategic shift to focus on the surgical market, which may not yield expected results.
• The company is dependent on key personnel and the loss of such individuals could adversely affect operations.
• The company's financial performance has been characterized by net losses, which may continue if commercialization efforts are not successful.

Future Outlook

The company is shifting its strategy to focus on developing and commercializing transformative products to improve clinical outcomes and reduce healthcare expenditures in the surgical market, while discontinuing non-core operations like Tissue Health Plus.

Management Comments

• The Board believes that the separation of the Executive Chairman and CEO roles facilitates strategic planning and operational focus.
• The Board believes that an advisory vote on executive compensation every three years is appropriate to evaluate long-term business results.

Industry Context

StockSavvy.ai notes that Sanara MedTech is navigating a challenging period of strategic realignment common in the medical technology sector, where companies often pivot from R&D-heavy or diversified portfolios to focus on high-margin surgical applications to improve profitability.

Comparison to Industry Standards

• The company's use of a virtual-only meeting format is consistent with modern corporate practices to increase shareholder participation and reduce costs.
• The compensation structure, including restricted stock grants and performance-based bonuses, aligns with standard practices for small-cap medical technology firms.
• The reliance on independent directors for committee chairs meets Nasdaq listing requirements.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Transaction Advisory Services Agreement with The Catalyst Group, Inc. (affiliated with Executive Chairman Ronald T. Nixon).
• Product License Agreements with Rochal Industries, LLC (affiliated with Ronald T. Nixon and Ann Beal Salamone).
• Consulting Agreement with director Ann Beal Salamone.

Stakeholder Impact

• Shareholders are requested to vote on key governance and compensation matters.
• Employees and management are impacted by the strategic shift and discontinuation of certain business units.

Next Steps

• Hold the Annual Meeting of Shareholders on June 4, 2026.
• File the voting results in a Current Report on Form 8-K within four business days after the meeting.
• Continue the strategic focus on the surgical market.

Key Dates

Recommendation

The company is in a transition phase with significant losses and a strategic pivot; investors should wait for evidence of improved operational efficiency and successful commercialization of the new surgical product focus before increasing positions.

Keywords

Sanara MedTech, SMTI, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Medical Technology